

David W Dowdy

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7411317/publications.pdf>

Version: 2024-02-01

269
papers

11,972
citations

41344

49
h-index

32842

100
g-index

280
all docs

280
docs citations

280
times ranked

13989
citing authors

#	ARTICLE	IF	CITATIONS
1	Tuberculosis. Nature Reviews Disease Primers, 2016, 2, 16076.	30.5	830
2	Gamma Interferon Release Assays for Detection of Mycobacterium tuberculosis Infection. Clinical Microbiology Reviews, 2014, 27, 3-20.	13.6	662
3	Neuromuscular dysfunction acquired in critical illness: a systematic review. Intensive Care Medicine, 2007, 33, 1876-1891.	8.2	527
4	Physical Complications in Acute Lung Injury Survivors. Critical Care Medicine, 2014, 42, 849-859.	0.9	480
5	Quality of life in adult survivors of critical illness: A systematic review of the literature. Intensive Care Medicine, 2005, 31, 611-620.	8.2	460
6	The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis. Lancet Respiratory Medicine, the, 2017, 5, 291-360.	10.7	459
7	Feasibility, accuracy, and clinical effect of point-of-care Xpert MTB/RIF testing for tuberculosis in primary-care settings in Africa: a multicentre, randomised, controlled trial. Lancet, The, 2014, 383, 424-435.	13.7	379
8	Incipient and Subclinical Tuberculosis: a Clinical Review of Early Stages and Progression of Infection. Clinical Microbiology Reviews, 2018, 31, .	13.6	353
9	Adherence to Nonnucleoside Reverse Transcriptase Inhibitor-Based HIV Therapy and Virologic Outcomes. Annals of Internal Medicine, 2007, 146, 564.	3.9	318
10	Quality of life after acute respiratory distress syndrome: a meta-analysis. Intensive Care Medicine, 2006, 32, 1115-1124.	8.2	316
11	Lower Pill Burden and Once-Daily Antiretroviral Treatment Regimens for HIV Infection: A Meta-Analysis of Randomized Controlled Trials. Clinical Infectious Diseases, 2014, 58, 1297-1307.	5.8	293
12	Advancing global health and strengthening the HIV response in the era of the Sustainable Development Goals: the International AIDS Society's Lancet Commission. Lancet, The, 2018, 392, 312-358.	13.7	230
13	Sudden Cardiac Death in Patients With Human Immunodeficiency Virus Infection. Journal of the American College of Cardiology, 2012, 59, 1891-1896.	2.8	228
14	A call to action for comprehensive HIV services for men who have sex with men. Lancet, The, 2012, 380, 424-438.	13.7	226
15	The potential impact of the COVID-19 pandemic on the tuberculosis epidemic a modelling analysis. EClinicalMedicine, 2020, 28, 100603.	7.1	203
16	What We Know About Tuberculosis Transmission: An Overview. Journal of Infectious Diseases, 2017, 216, S629-S635.	4.0	193
17	Burden of transmitted multidrug resistance in epidemics of tuberculosis: a transmission modelling analysis. Lancet Respiratory Medicine, the, 2015, 3, 963-972.	10.7	165
18	Do high rates of empirical treatment undermine the potential effect of new diagnostic tests for tuberculosis in high-burden settings?. Lancet Infectious Diseases, The, 2014, 14, 527-532.	9.1	141

#	ARTICLE	IF	CITATIONS
19	Sustainable HIV treatment in Africa through viral-load-informed differentiated care. <i>Nature</i> , 2015, 528, S68-S76.	27.8	141
20	Feasibility of achieving the 2025 WHO global tuberculosis targets in South Africa, China, and India: a combined analysis of 11 mathematical models. <i>The Lancet Global Health</i> , 2016, 4, e806-e815.	6.3	138
21	Heterogeneity in tuberculosis transmission and the role of geographic hotspots in propagating epidemics. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 9557-9562.	7.1	132
22	The Relationship of COVID-19 Severity with Cardiovascular Disease and Its Traditional Risk Factors: A Systematic Review and Meta-Analysis. <i>Global Heart</i> , 2020, 15, 64.	2.3	115
23	Understanding the incremental value of novel diagnostic tests for tuberculosis. <i>Nature</i> , 2015, 528, S60-S67.	27.8	114
24	Is Passive Diagnosis Enough?. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2013, 187, 543-551.	5.6	103
25	Point-of-care C-reactive protein-based tuberculosis screening for people living with HIV: a diagnostic accuracy study. <i>Lancet Infectious Diseases</i> , The, 2017, 17, 1285-1292.	9.1	96
26	The Lancet Respiratory Medicine Commission: 2019 update: epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant and incurable tuberculosis. <i>Lancet Respiratory Medicine</i> , the, 2019, 7, 820-826.	10.7	92
27	Optimal Timing of Antiretroviral Therapy Initiation for HIV-Infected Adults With Newly Diagnosed Pulmonary Tuberculosis. <i>Annals of Internal Medicine</i> , 2015, 163, 32-39.	3.9	91
28	Data for action: collection and use of local data to end tuberculosis. <i>Lancet</i> , The, 2015, 386, 2324-2333.	13.7	89
29	Impact of enhanced tuberculosis diagnosis in South Africa: A mathematical model of expanded culture and drug susceptibility testing. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 11293-11298.	7.1	87
30	The Epidemiological Importance of Subclinical Tuberculosis. A Critical Reappraisal. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 203, 168-174.	5.6	87
31	Breaking the Translational Barriers: The Value of Integrating Biomedical Informatics and Translational Research. <i>Journal of Investigative Medicine</i> , 2005, 53, 192-200.	1.6	86
32	Timing of Tuberculosis Transmission and the Impact of Household Contact Tracing. An Agent-based Simulation Model. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2014, 189, 845-852.	5.6	80
33	The Epidemiologic and Economic Impact of Improving HIV Testing, Linkage, and Retention in Care in the United States. <i>Clinical Infectious Diseases</i> , 2016, 62, 220-229.	5.8	79
34	Intensive care unit hypoglycemia predicts depression during early recovery from acute lung injury*. <i>Critical Care Medicine</i> , 2008, 36, 2726-2733.	0.9	78
35	Are intensive care factors associated with depressive symptoms 6 months after acute lung injury?*. <i>Critical Care Medicine</i> , 2009, 37, 1702-1707.	0.9	77
36	How much is tuberculosis screening worth? Estimating the value of active case finding for tuberculosis in South Africa, China, and India. <i>BMC Medicine</i> , 2014, 12, 216.	5.5	77

#	ARTICLE	IF	CITATIONS
37	Identifying barriers to and facilitators of tuberculosis contact investigation in Kampala, Uganda: a behavioral approach. <i>Implementation Science</i> , 2017, 12, 33.	6.9	77
38	Sensitivity of direct versus concentrated sputum smear microscopy in HIV-infected patients suspected of having pulmonary tuberculosis. <i>BMC Infectious Diseases</i> , 2009, 9, 53.	2.9	71
39	Cost-effectiveness and resource implications of aggressive action on tuberculosis in China, India, and South Africa: a combined analysis of nine models. <i>The Lancet Global Health</i> , 2016, 4, e816-e826.	6.3	69
40	The Importance of Heterogeneity to the Epidemiology of Tuberculosis. <i>Clinical Infectious Diseases</i> , 2019, 69, 159-166.	5.8	68
41	The potential impact of enhanced diagnostic techniques for tuberculosis driven by HIV: a mathematical model. <i>Aids</i> , 2006, 20, 751-762.	2.2	67
42	Serological Testing Versus Other Strategies for Diagnosis of Active Tuberculosis in India: A Cost-Effectiveness Analysis. <i>PLoS Medicine</i> , 2011, 8, e1001074.	8.4	63
43	Alignment of new tuberculosis drug regimens and drug susceptibility testing: a framework for action. <i>Lancet Infectious Diseases</i> , The, 2013, 13, 449-458.	9.1	59
44	Differentiated Care Preferences of Stable Patients on Antiretroviral Therapy in Zambia: A Discrete Choice Experiment. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 81, 540-546.	2.1	58
45	The persistence of tuberculosis in the age of DOTS: reassessing the effect of case detection. <i>Bulletin of the World Health Organization</i> , 2009, 87, 296-304.	3.3	57
46	Is Scale-Up Worth It? Challenges in Economic Analysis of Diagnostic Tests for Tuberculosis. <i>PLoS Medicine</i> , 2011, 8, e1001063.	8.4	56
47	Studying outcomes of intensive care unit survivors: measuring exposures and outcomes. <i>Intensive Care Medicine</i> , 2005, 31, 1153-1160.	8.2	54
48	Bridging the gap between evidence and policy for infectious diseases: How models can aid public health decision-making. <i>International Journal of Infectious Diseases</i> , 2016, 42, 17-23.	3.3	54
49	Clinical Effectiveness and Cost-Effectiveness of HIV Pre-Exposure Prophylaxis in Men Who Have Sex with Men: Risk Calculators for Real-World Decision-Making. <i>PLoS ONE</i> , 2014, 9, e108742.	2.5	53
50	The impact of new tuberculosis diagnostics on transmission: why context matters. <i>Bulletin of the World Health Organization</i> , 2012, 90, 739-747.	3.3	51
51	Estimated clinical impact of the Xpert MTB/RIF Ultra cartridge for diagnosis of pulmonary tuberculosis: A modeling study. <i>PLoS Medicine</i> , 2017, 14, e1002472.	8.4	50
52	Stopping the body count: a comprehensive approach to move towards zero tuberculosis deaths. <i>Lancet, The</i> , 2015, 386, e46-e47.	13.7	48
53	Cost-Effectiveness Analysis of the Gen-Probe Amplified Mycobacterium Tuberculosis Direct Test as Used Routinely on Smear-Positive Respiratory Specimens. <i>Journal of Clinical Microbiology</i> , 2003, 41, 948-953.	3.9	44
54	Impact and Cost-Effectiveness of Culture for Diagnosis of Tuberculosis in HIV-Infected Brazilian Adults. <i>PLoS ONE</i> , 2008, 3, e4057.	2.5	44

#	ARTICLE	IF	CITATIONS
55	Challenges in the Evaluation of Interventions to Improve Engagement Along the HIV Care Continuum in the United States: A Systematic Review. <i>AIDS and Behavior</i> , 2017, 21, 2101-2123.	2.7	44
56	Cost-effectiveness of Preventive Therapy for Tuberculosis With Isoniazid and Rifapentine Versus Isoniazid Alone in High-Burden Settings. <i>Clinical Infectious Diseases</i> , 2018, 67, 1072-1078.	5.8	43
57	Costing the implementation of public health interventions in resource-limited settings: a conceptual framework. <i>Implementation Science</i> , 2020, 15, 86.	6.9	43
58	The Importance of Implementation Strategy in Scaling Up Xpert MTB/RIF for Diagnosis of Tuberculosis in the Indian Health-Care System: A Transmission Model. <i>PLoS Medicine</i> , 2014, 11, e1001674.	8.4	42
59	Effect of the US National HIV/AIDS Strategy targets for improved HIV care engagement: a modelling study. <i>Lancet HIV</i> , 2016, 3, e140-e146.	4.7	42
60	Implementation of Xpert MTB/RIF in Uganda: Missed Opportunities to Improve Diagnosis of Tuberculosis. <i>Open Forum Infectious Diseases</i> , 2016, 3, ofw068.	0.9	42
61	Spatially targeted screening to reduce tuberculosis transmission in high-incidence settings. <i>Lancet Infectious Diseases</i> , 2019, 19, e89-e95.	9.1	41
62	The Distribution of Fitness Costs of Resistance-Confering Mutations Is a Key Determinant for the Future Burden of Drug-Resistant Tuberculosis: A Model-Based Analysis. <i>Clinical Infectious Diseases</i> , 2015, 61, S147-S154.	5.8	40
63	Quantifying the potential value of antigen-detection rapid diagnostic tests for COVID-19: a modelling analysis. <i>BMC Medicine</i> , 2021, 19, 75.	5.5	40
64	Transforming the Fight Against Tuberculosis: Targeting Catalysts of Transmission. <i>Clinical Infectious Diseases</i> , 2014, 59, 1123-1129.	5.8	37
65	Economic Evaluation of Laboratory Testing Strategies for Hospital-Associated <i>Clostridium difficile</i> Infection. <i>Journal of Clinical Microbiology</i> , 2014, 52, 489-496.	3.9	37
66	Contact tracing versus facility-based screening for active TB case finding in rural South Africa: A pragmatic cluster-randomized trial (Kharitode TB). <i>PLoS Medicine</i> , 2019, 16, e1002796.	8.4	36
67	Yield and Efficiency of Novel Intensified Tuberculosis Case-Finding Algorithms for People Living with HIV. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019, 199, 643-650.	5.6	36
68	Rapid Molecular Testing for TB to Guide Respiratory Isolation in the U.S.: A Cost-Benefit Analysis. <i>PLoS ONE</i> , 2013, 8, e79669.	2.5	35
69	Drop-out from the tuberculosis contact investigation cascade in a routine public health setting in urban Uganda: A prospective, multi-center study. <i>PLoS ONE</i> , 2017, 12, e0187145.	2.5	35
70	Integrating social justice concerns into economic evaluation for healthcare and public health: A systematic review. <i>Social Science and Medicine</i> , 2018, 198, 27-35.	3.8	34
71	Country-wide distribution of the nitrile female condom (FC2) in Brazil and South Africa: a cost-effectiveness analysis. <i>Aids</i> , 2006, 20, 2091-2098.	2.2	33
72	Severe mental illness at ART initiation is associated with worse retention in care among HIV-infected Ugandan adults. <i>Tropical Medicine and International Health</i> , 2013, 18, 53-57.	2.3	33

#	ARTICLE	IF	CITATIONS
73	Guidance for Studies Evaluating the Accuracy of Tuberculosis Triage Tests. <i>Journal of Infectious Diseases</i> , 2019, 220, S116-S125.	4.0	33
74	Point of care Xpert MTB/RIF versus smear microscopy for tuberculosis diagnosis in southern African primary care clinics: a multicentre economic evaluation. <i>The Lancet Global Health</i> , 2019, 7, e798-e807.	6.3	33
75	Levofloxacin versus placebo for the treatment of latent tuberculosis among contacts of patients with multidrug-resistant tuberculosis (the VQUIN MDR trial): a protocol for a randomised controlled trial. <i>BMJ Open</i> , 2020, 10, e033945.	1.9	33
76	Studying outcomes of intensive care unit survivors: the role of the cohort study. <i>Intensive Care Medicine</i> , 2005, 31, 914-921.	8.2	31
77	Modeling the Impact of Alternative Strategies for Rapid Molecular Diagnosis of Tuberculosis in Southeast Asia. <i>American Journal of Epidemiology</i> , 2013, 178, 1740-1749.	3.4	31
78	Yield of household contact tracing for tuberculosis in rural South Africa. <i>BMC Infectious Diseases</i> , 2018, 18, 299.	2.9	31
79	Digital adherence technology for tuberculosis treatment supervision: A stepped-wedge cluster-randomized trial in Uganda. <i>PLoS Medicine</i> , 2021, 18, e1003628.	8.4	31
80	MDR-TB treatment as prevention: The projected population-level impact of expanded treatment for multidrug-resistant tuberculosis. <i>PLoS ONE</i> , 2017, 12, e0172748.	2.5	30
81	Population-Level Impact of Active Tuberculosis Case Finding in an Asian Megacity. <i>PLoS ONE</i> , 2013, 8, e77517.	2.5	28
82	Are we underestimating the annual risk of infection with <i>Mycobacterium tuberculosis</i> in high-burden settings?. <i>Lancet Infectious Diseases</i> , The, 2022, 22, e271-e278.	9.1	28
83	Latent Tuberculosis: Models, Computational Efforts and the Pathogen's Regulatory Mechanisms during Dormancy. <i>Frontiers in Bioengineering and Biotechnology</i> , 2013, 1, 4.	4.1	27
84	Serial testing for latent tuberculosis using QuantiFERON-TB Gold In-Tube: A Markov model. <i>Scientific Reports</i> , 2016, 6, 30781.	3.3	27
85	Treatment of latent infection to achieve tuberculosis elimination in low-incidence countries. <i>PLoS Medicine</i> , 2019, 16, e1002824.	8.4	27
86	Do We Need to Detect Isoniazid Resistance in Addition to Rifampicin Resistance in Diagnostic Tests for Tuberculosis?. <i>PLoS ONE</i> , 2014, 9, e84197.	2.5	26
87	Designing and Evaluating Interventions to Halt the Transmission of Tuberculosis. <i>Journal of Infectious Diseases</i> , 2017, 216, S654-S661.	4.0	26
88	A Systematic Review to Evaluate the Association between Clean Cooking Technologies and Time Use in Low- and Middle-Income Countries. <i>International Journal of Environmental Research and Public Health</i> , 2019, 16, 2277.	2.6	26
89	Performance of a Novel Algorithm Using Automated Digital Microscopy for Diagnosing Tuberculosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2015, 191, 1443-1449.	5.6	25
90	Comparing Drivers and Dynamics of Tuberculosis in California, Florida, New York, and Texas. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017, 196, 1050-1059.	5.6	25

#	ARTICLE	IF	CITATIONS
91	Optimal costs of HIV pre-exposure prophylaxis for men who have sex with men. PLoS ONE, 2017, 12, e0178170.	2.5	25
92	Impact of Isoniazid Preventive Therapy for HIV-Infected Adults in Rio de Janeiro, Brazil. Journal of Acquired Immune Deficiency Syndromes (1999), 2014, 66, 552-558.	2.1	24
93	Mathematical Modelling and Tuberculosis: Advances in Diagnostics and Novel Therapies. Advances in Medicine, 2015, 2015, 1-10.	0.8	24
94	What if They Don't Have Tuberculosis? The Consequences and Trade-offs Involved in False-positive Diagnoses of Tuberculosis. Clinical Infectious Diseases, 2019, 68, 150-156.	5.8	24
95	Modeling Mitigation Strategies to Reduce Opioid-Related Morbidity and Mortality in the US. JAMA Network Open, 2020, 3, e2023677.	5.9	24
96	Effect of 2 Integrated Interventions on Alcohol Abstinence and Viral Suppression Among Vietnamese Adults With Hazardous Alcohol Use and HIV. JAMA Network Open, 2020, 3, e2017115.	5.9	24
97	The public health response to COVID-19: balancing precaution and unintended consequences. Annals of Epidemiology, 2020, 46, 12-13.	1.9	24
98	The Spectrum of Tuberculosis Disease in an Urban Ugandan Community and Its Health Facilities. Clinical Infectious Diseases, 2021, 72, e1035-e1043.	5.8	24
99	Cost-effectiveness of Targeted Human Immunodeficiency Virus Screening in an Urban Emergency Department. Academic Emergency Medicine, 2011, 18, 745-753.	1.8	23
100	C-Reactive Protein (CRP), Interferon Gamma-Inducible Protein 10 (IP-10), and Lipopolysaccharide (LPS) Are Associated with Risk of Tuberculosis after Initiation of Antiretroviral Therapy in Resource-Limited Settings. PLoS ONE, 2015, 10, e0117424.	2.5	23
101	Expected effects of adopting a 9 month regimen for multidrug-resistant tuberculosis: a population modelling analysis. Lancet Respiratory Medicine, the, 2017, 5, 191-199.	10.7	23
102	Challenges with scale-up of GeneXpert MTB/RIF® in Uganda: a health systems perspective. BMC Health Services Research, 2020, 20, 162.	2.2	23
103	Modeling of Novel Diagnostic Strategies for Active Tuberculosis – A Systematic Review: Current Practices and Recommendations. PLoS ONE, 2014, 9, e110558.	2.5	23
104	Effects of nelfinavir and its M8 metabolite on lymphocyte P-glycoprotein activity during antiretroviral therapy. Clinical Pharmacology and Therapeutics, 2003, 73, 78-86.	4.7	22
105	Population-Level Impact of Same-Day Microscopy and Xpert MTB/RIF for Tuberculosis Diagnosis in Africa. PLoS ONE, 2013, 8, e70485.	2.5	22
106	Improving active case finding for tuberculosis in South Africa: informing innovative implementation approaches in the context of the Kharitode trial through formative research. Health Research Policy and Systems, 2017, 15, 42.	2.8	22
107	Screening for tuberculosis: time to move beyond symptoms. Lancet Respiratory Medicine, the, 2019, 7, 202-204.	10.7	22
108	Screening for Tuberculosis With Xpert MTB/RIF Assay Versus Fluorescent Microscopy Among Adults Newly Diagnosed With Human Immunodeficiency Virus in Rural Malawi: A Cluster Randomized Trial (Chepetsa). Clinical Infectious Diseases, 2019, 68, 1176-1183.	5.8	21

#	ARTICLE	IF	CITATIONS
109	Empiric treatment of pulmonary TB in the Xpert era: Correspondence of sputum culture, Xpert MTB/RIF, and clinical diagnoses. <i>PLoS ONE</i> , 2019, 14, e0220251.	2.5	20
110	Seventy Years of Tuberculosis Prevention: Efficacy, Effectiveness, Toxicity, Durability, and Duration. <i>American Journal of Epidemiology</i> , 2019, 188, 2078-2085.	3.4	20
111	Model-based Cost-effectiveness of State-level Latent Tuberculosis Interventions in California, Florida, New York, and Texas. <i>Clinical Infectious Diseases</i> , 2021, 73, e3476-e3482.	5.8	20
112	Priority-Setting for Novel Drug Regimens to Treat Tuberculosis: An Epidemiologic Model. <i>PLoS Medicine</i> , 2017, 14, e1002202.	8.4	20
113	An agent-based simulation of a Tuberculosis epidemic: Understanding the timing of transmission. , 2013, , .		19
114	Informing decision-making for universal access to quality tuberculosis diagnosis in India: an economic-epidemiological model. <i>BMC Medicine</i> , 2019, 17, 155.	5.5	19
115	Potential impact of spatially targeted adult tuberculosis vaccine in Gujarat, India. <i>Journal of the Royal Society Interface</i> , 2016, 13, 20151016.	3.4	18
116	Siyaphambili protocol: An evaluation of randomized, nurse-led adaptive HIV treatment interventions for cisgender female sex workers living with HIV in Durban, South Africa. <i>Research in Nursing and Health</i> , 2019, 42, 107-118.	1.6	18
117	Screening for Tuberculosis Among Adults Newly Diagnosed With HIV in Sub-Saharan Africa. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2015, 70, 83-90.	2.1	17
118	A Multistrain Mathematical Model To Investigate the Role of Pyrazinamide in the Emergence of Extensively Drug-Resistant Tuberculosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	17
119	Research Roadmap for Tuberculosis Transmission Science: Where Do We Go From Here and How Will We Know When We're There?. <i>Journal of Infectious Diseases</i> , 2017, 216, S662-S668.	4.0	17
120	How Do Urban Indian Private Practitioners Diagnose and Treat Tuberculosis? A Cross-Sectional Study in Chennai. <i>PLoS ONE</i> , 2016, 11, e0149862.	2.5	17
121	Serological tests for the diagnosis of active tuberculosis: relevance for India. <i>Indian Journal of Medical Research</i> , 2012, 135, 695-702.	1.0	16
122	Drivers and Trajectories of Resistance to New First-Line Drug Regimens for Tuberculosis. <i>Open Forum Infectious Diseases</i> , 2014, 1, ofu073.	0.9	15
123	The Ethics of Testing a Test: Randomized Trials of the Health Impact of Diagnostic Tests for Infectious Diseases. <i>Clinical Infectious Diseases</i> , 2012, 55, 1522-1526.	5.8	14
124	Challenges in Evaluating the Cost-effectiveness of New Diagnostic Tests for HIV-Associated Tuberculosis. <i>Clinical Infectious Diseases</i> , 2013, 57, 1021-1026.	5.8	14
125	Second line drug susceptibility testing to inform the treatment of rifampin-resistant tuberculosis: a quantitative perspective. <i>International Journal of Infectious Diseases</i> , 2017, 56, 185-189.	3.3	14
126	Aminoglycoside-induced Hearing Loss Among Patients Being Treated for Drug-resistant Tuberculosis in South Africa: A Prediction Model. <i>Clinical Infectious Diseases</i> , 2020, 70, 917-924.	5.8	14

#	ARTICLE	IF	CITATIONS
127	Study protocol: a cluster randomized trial to evaluate the effectiveness and implementation of onsite GeneXpert testing at community health centers in Uganda (XPEL-TB). <i>Implementation Science</i> , 2020, 15, 24.	6.9	14
128	Cost-effectiveness of scaling up short course preventive therapy for tuberculosis among children across 12 countries. <i>EClinicalMedicine</i> , 2021, 31, 100707.	7.1	14
129	Economic and epidemiological impact of early antiretroviral therapy initiation in India. <i>Journal of the International AIDS Society</i> , 2015, 18, 20217.	3.0	13
130	Of Testing and Treatment: Implications of Implementing New Regimens for Multidrug-Resistant Tuberculosis. <i>Clinical Infectious Diseases</i> , 2017, 65, 1206-1211.	5.8	13
131	Impact of Targeted Tuberculosis Vaccination Among a Mining Population in South Africa: A Model-Based Study. <i>American Journal of Epidemiology</i> , 2017, 186, 1362-1369.	3.4	13
132	Impact and Effectiveness of State-Level Tuberculosis Interventions in California, Florida, New York, and Texas: A Model-Based Analysis. <i>American Journal of Epidemiology</i> , 2019, 188, 1733-1741.	3.4	13
133	Comparative Modeling of Tuberculosis Epidemiology and Policy Outcomes in California. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 201, 356-365.	5.6	13
134	Is distance associated with tuberculosis treatment outcomes? A retrospective cohort study in Kampala, Uganda. <i>BMC Infectious Diseases</i> , 2020, 20, 406.	2.9	13
135	Integrated screening and treatment services for HIV, hypertension and diabetes in Kenya: assessing the epidemiological impact and cost-effectiveness from a national and regional perspective. <i>Journal of the International AIDS Society</i> , 2020, 23, e25499.	3.0	13
136	Costs and cost-effectiveness of a comprehensive tuberculosis case finding strategy in Zambia. <i>PLoS ONE</i> , 2021, 16, e0256531.	2.5	13
137	A clinical score for identifying active tuberculosis while awaiting microbiological results: Development and validation of a multivariable prediction model in sub-Saharan Africa. <i>PLoS Medicine</i> , 2020, 17, e1003420.	8.4	13
138	Costs and Consequences of Using Interferon- γ Release Assays for the Diagnosis of Active Tuberculosis in India. <i>PLoS ONE</i> , 2015, 10, e0124525.	2.5	13
139	Multicomponent Strategy with Decentralized Molecular Testing for Tuberculosis. <i>New England Journal of Medicine</i> , 2021, 385, 2441-2450.	27.0	13
140	Cost-effectiveness of Diagnostic Algorithms for Tuberculosis in Children Less Than 5 Years of Age. <i>Pediatric Infectious Disease Journal</i> , 2017, 36, 36-43.	2.0	12
141	Mathematical Modeling of "Chronic" Infectious Diseases: Unpacking the Black Box. <i>Open Forum Infectious Diseases</i> , 2017, 4, ofx172.	0.9	12
142	Current and future trends in tuberculosis incidence in New York City: a dynamic modelling analysis. <i>Lancet Public Health</i> , The, 2017, 2, e323-e330.	10.0	12
143	What Will It Take to End HIV in the United States?. <i>Annals of Internal Medicine</i> , 2021, 174, 1542-1553.	3.9	12
144	A user-friendly, open-source tool to project impact and cost of diagnostic tests for tuberculosis. <i>ELife</i> , 2014, 3, .	6.0	12

#	ARTICLE	IF	CITATIONS
145	Impact of Providing Preexposure Prophylaxis for Human Immunodeficiency Virus at Clinics for Sexually Transmitted Infections in Baltimore City: An Agent-based Model. <i>Sexually Transmitted Diseases</i> , 2018, 45, 791-797.	1.7	11
146	Economic and epidemiologic impact of guidelines for early ART initiation irrespective of CD4 count in Spain. <i>PLoS ONE</i> , 2018, 13, e0206755.	2.5	11
147	Maternal priorities for preventive therapy among HIV-positive pregnant women before and after delivery in South Africa: a "best" worst scaling survey. <i>Journal of the International AIDS Society</i> , 2018, 21, e25143.	3.0	11
148	Operational characteristics of antiretroviral therapy clinics in Zambia: a time and motion analysis. <i>BMC Health Services Research</i> , 2019, 19, 244.	2.2	11
149	Study protocol and implementation details for a pragmatic, stepped-wedge cluster randomised trial of a digital adherence technology to facilitate tuberculosis treatment completion. <i>BMJ Open</i> , 2020, 10, e039895.	1.9	11
150	Population-Level Impact of Shorter-Course Regimens for Tuberculosis: A Model-Based Analysis. <i>PLoS ONE</i> , 2014, 9, e96389.	2.5	10
151	The impact of novel tests for tuberculosis depends on the diagnostic cascade. <i>European Respiratory Journal</i> , 2014, 44, 1366-1369.	6.7	10
152	Reducing relapse in tuberculosis treatment: is it time to reassess WHO treatment guidelines?. <i>International Journal of Tuberculosis and Lung Disease</i> , 2015, 19, 624-624.	1.2	10
153	The Impact and Cost-Effectiveness of a Four-Month Regimen for First-Line Treatment of Active Tuberculosis in South Africa. <i>PLoS ONE</i> , 2015, 10, e0145796.	2.5	10
154	Brief Report: "Give Me Some Time" Facilitators of and Barriers to Uptake of Home-Based HIV Testing During Household Contact Investigation for Tuberculosis in Kampala, Uganda. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018, 77, 400-404.	2.1	10
155	From Epidemiologic Knowledge to Improved Health: A Vision for Translational Epidemiology. <i>American Journal of Epidemiology</i> , 2019, 188, 2049-2060.	3.4	10
156	Bridging the Gap Between Knowledge and Health. <i>Epidemiology</i> , 2012, 23, 914-918.	2.7	9
157	Ancient Disease, Modern Epidemiology: A Century of Progress in Understanding and Fighting Tuberculosis. <i>American Journal of Epidemiology</i> , 2016, 183, 407-414.	3.4	9
158	Spatial distribution of people diagnosed with tuberculosis through routine and active case finding: a community-based study in Kampala, Uganda. <i>Infectious Diseases of Poverty</i> , 2020, 9, 73.	3.7	9
159	Cost-Effectiveness of Automated Digital Microscopy for Diagnosis of Active Tuberculosis. <i>PLoS ONE</i> , 2016, 11, e0157554.	2.5	9
160	Achieving a "step change" in the tuberculosis epidemic through comprehensive community-wide intervention: a model-based analysis. <i>BMC Medicine</i> , 2021, 19, 244.	5.5	9
161	Mortality Among Antiretroviral-Eligible Patients in an Urban Public Clinic. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2011, 57, 297-300.	2.1	8
162	Risk Factors for Delirium. <i>Critical Care Medicine</i> , 2015, 43, 232-233.	0.9	8

#	ARTICLE	IF	CITATIONS
163	Maternal Motivation to Take Preventive Therapy in Antepartum and Postpartum Among HIV-Positive Pregnant Women in South Africa: A Choice Experiment. <i>AIDS and Behavior</i> , 2019, 23, 1689-1697.	2.7	8
164	Protocol for the 3HP Options Trial: a hybrid type 3 implementation-effectiveness randomized trial of delivery strategies for short-course tuberculosis preventive therapy among people living with HIV in Uganda. <i>Implementation Science</i> , 2020, 15, 65.	6.9	8
165	Patient choice improves self-efficacy and intention to complete tuberculosis preventive therapy in a routine HIV program setting in Uganda. <i>PLoS ONE</i> , 2021, 16, e0246113.	2.5	8
166	The longitudinal association between depression, anxiety symptoms and HIV outcomes, and the modifying effect of alcohol dependence among ART clients with hazardous alcohol use in Vietnam. <i>Journal of the International AIDS Society</i> , 2021, 24, e25746.	3.0	8
167	Alcohol abstinence stigma and alcohol use among HIV patients in Thai Nguyen, Vietnam. <i>PLoS ONE</i> , 2020, 15, e0239330.	2.5	8
168	Cost and Cost-Effectiveness of a Digital Adherence Technology for Tuberculosis Treatment Support in Uganda. <i>Value in Health</i> , 2022, 25, 924-930.	0.3	8
169	A Novel Tool Improves Existing Estimates of Recent Tuberculosis Transmission in Settings of Sparse Data Collection. <i>PLoS ONE</i> , 2015, 10, e0144137.	2.5	7
170	Cost-effectiveness of triage testing for facility-based systematic screening of tuberculosis among Ugandan adults. <i>BMJ Global Health</i> , 2016, 1, e000064.	4.7	7
171	Projected population-wide impact of antiretroviral therapy-linked isoniazid preventive therapy in a high-burden setting. <i>Aids</i> , 2019, 33, 525-536.	2.2	7
172	Towards evidence-based integration of services for HIV, non-communicable diseases and substance use: insights from modelling. <i>Journal of the International AIDS Society</i> , 2020, 23, e25525.	3.0	7
173	Implementation of two alcohol reduction interventions among persons with hazardous alcohol use who are living with HIV in Thai Nguyen, Vietnam: a micro-costing analysis. <i>Global Health Action</i> , 2020, 13, 1814035.	1.9	7
174	The Cost-Effectiveness of Adapting and Implementing a Brief Intervention to Target Frequent Alcohol Use Among Persons with HIV in Vietnam. <i>AIDS and Behavior</i> , 2021, 25, 2108-2119.	2.7	7
175	Effect of reductions in opioid prescribing on opioid use disorder and fatal overdose in the United States: a dynamic Markov model. <i>Addiction</i> , 2022, 117, 969-976.	3.3	7
176	Evidence-based COVID-19 policy-making in schools. <i>Nature Medicine</i> , 2021, 27, 2078-2079.	30.7	7
177	Tobacco Smoking and Bladder Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2011, 306, 2216.	7.4	6
178	Drug-resistant tuberculosis in 2017: at a crossroads. <i>Lancet Respiratory Medicine</i> , 2017, 5, 241-242.	10.7	6
179	What Will It Take to Reduce HIV Incidence in the United States: A Mathematical Modeling Analysis. <i>Open Forum Infectious Diseases</i> , 2018, 5, ofy008.	0.9	6
180	Estimating the impact of a novel drug regimen for treatment of tuberculosis: a modeling analysis of projected patient outcomes and epidemiological considerations. <i>BMC Infectious Diseases</i> , 2019, 19, 794.	2.9	6

#	ARTICLE	IF	CITATIONS
181	Quality of care for patients evaluated for tuberculosis in the context of Xpert MTB/RIF scale-up. <i>Journal of Clinical Tuberculosis and Other Mycobacterial Diseases</i> , 2019, 15, 100099.	1.3	6
182	Cost-effectiveness of one month of daily isoniazid and rifapentine versus three months of weekly isoniazid and rifapentine for prevention of tuberculosis among people receiving antiretroviral therapy in Uganda. <i>Journal of the International AIDS Society</i> , 2020, 23, e25623.	3.0	6
183	Redefining and revisiting cost estimates of routine ART care in Zambia: an analysis of ten clinics. <i>Journal of the International AIDS Society</i> , 2020, 23, e25431.	3.0	6
184	Characterization of geographic mobility among participants in facility- and community-based tuberculosis case finding in urban Uganda. <i>PLoS ONE</i> , 2021, 16, e0251806.	2.5	6
185	Acceptance and completion of rifapentine-based TB preventive therapy (3HP) among people living with HIV (PLHIV) in Kampala, Uganda—patient and health worker perspectives. <i>Implementation Science Communications</i> , 2021, 2, 71.	2.2	6
186	Potential Effects of the Coronavirus Disease 2019 (COVID-19) Pandemic on Human Immunodeficiency Virus (HIV) Transmission: A Modeling Study in 32 US Cities. <i>Clinical Infectious Diseases</i> , 2022, 75, e1145-e1153.	5.8	6
187	A cost analysis of implementing mobile health facilitated tuberculosis contact investigation in a low-income setting. <i>PLoS ONE</i> , 2022, 17, e0265033.	2.5	6
188	Completion of isoniazid-rifapentine (3HP) for tuberculosis prevention among people living with HIV: Interim analysis of a hybrid type 3 effectiveness-implementation randomized trial. <i>PLoS Medicine</i> , 2021, 18, e1003875.	8.4	6
189	Patient Follow-up in an Urban Resident Continuity Clinic: An Initiative to Improve Scheduling Practices. <i>Journal of Graduate Medical Education</i> , 2011, 3, 256-260.	1.3	5
190	Trained to Avoid Primary Care. <i>Annals of Internal Medicine</i> , 2011, 154, 776.	3.9	5
191	Economic evaluations of point of care testing strategies for active tuberculosis. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2013, 13, 313-325.	1.4	5
192	Evaluating the cost of adult voluntary medical male circumcision in a mixed (surgical and PrePex) site compared to a hypothetical PrePex-only site in South Africa. <i>Global Health Action</i> , 2015, 8, 29116.	1.9	5
193	Minding the Gap: Specimen Referral Systems for Diagnosis of Infectious Diseases. <i>Clinical Infectious Diseases</i> , 2017, 64, ciw820.	5.8	5
194	The effect of partner HIV status on motivation to take antiretroviral and isoniazid preventive therapies: a conjoint analysis. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2018, 30, 1298-1305.	1.2	5
195	Tuberculosis Incidence Among Populations at High Risk in California, Florida, New York, and Texas, 2011-2015. <i>American Journal of Public Health</i> , 2018, 108, S311-S314.	2.7	5
196	Would pan-tuberculosis treatment regimens be cost-effective?. <i>Lancet Respiratory Medicine</i> , 2018, 6, 486-488.	10.7	5
197	Gonorrhoea and chlamydia diagnosis as an entry point for HIV pre-exposure prophylaxis: a modelling study. <i>BMJ Open</i> , 2019, 9, e023453.	1.9	5
198	Comparing a standard and tailored approach to scaling up an evidence-based intervention for antiretroviral therapy for people who inject drugs in Vietnam: study protocol for a cluster randomized hybrid type III trial. <i>Implementation Science</i> , 2020, 15, 64.	6.9	5

#	ARTICLE	IF	CITATIONS
199	Quantifying geographic heterogeneity in TB incidence and the potential impact of geographically targeted interventions in South and North City Corporations of Dhaka, Bangladesh: a model-based study. <i>Epidemiology and Infection</i> , 2021, 149, e106.	2.1	5
200	Prevalence of Pre-Existing Hearing Loss Among Patients With Drug-Resistant Tuberculosis in South Africa. <i>American Journal of Audiology</i> , 2020, 29, 199-205.	1.2	5
201	Cost-effectiveness analysis of human-centred design for global health interventions: a quantitative framework. <i>BMJ Global Health</i> , 2022, 7, e007912.	4.7	5
202	Estimating the proportion of tuberculosis recent transmission via simulation. , 2014, , .		4
203	Point-of-Care Tests for HIV, Related Coinfections, and Blood-Borne Infections. <i>AIDS Research and Treatment</i> , 2014, 2014, 1-2.	0.7	4
204	Projecting the impact of variable MDR-TB transmission efficiency on long-term epidemic trends in South Africa and Vietnam. <i>Scientific Reports</i> , 2019, 9, 18099.	3.3	4
205	Cost-effectiveness of a 12 country intervention to scale up short course TB preventive therapy among people living with HIV. <i>Journal of the International AIDS Society</i> , 2020, 23, e25629.	3.0	4
206	Measuring Stigma to Assess the Social Justice Implications of Health-Related Policy Decisions: Application to Novel Treatment Regimens for Multidrug-Resistant Tuberculosis. <i>MDM Policy and Practice</i> , 2020, 5, 238146832091523.	0.9	4
207	Patient-incurred cost of inpatient treatment for Tuberculosis in rural Malawi. <i>Tropical Medicine and International Health</i> , 2020, 25, 624-634.	2.3	4
208	Effectiveness of low-dose theophylline for the management of biomass-associated COPD (LODOT-BCOPD): study protocol for a randomized controlled trial. <i>Trials</i> , 2021, 22, 213.	1.6	4
209	Validating novel diagnostic assays for tuberculosis in the context of existing tools. <i>The Lancet Global Health</i> , 2021, 9, e1209.	6.3	4
210	Has the COVID-19 pandemic increased tuberculosis mortality?. <i>Lancet Infectious Diseases</i> , The, 2022, 22, 165-166.	9.1	4
211	Health-related quality of life of female sex workers living with HIV in South Africa: a cross-sectional study. <i>Journal of the International AIDS Society</i> , 2022, 25, e25884.	3.0	4
212	Thinking outside the box. <i>Critical Care Medicine</i> , 2012, 40, 2231-2232.	0.9	3
213	Economic analyses of diagnostics for tuberculosis: what's the point?. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2012, 12, 137-139.	1.4	3
214	Tuberculosis: progress and challenges in product development and delivery. <i>Lancet Respiratory Medicine</i> , the, 2014, 2, 25-27.	10.7	3
215	Evaluating the effects of two alcohol reduction counseling interventions on intimate partner violence perpetration: secondary analysis of a three-arm randomized controlled trial among Vietnamese men with HIV. <i>Addiction</i> , 2021, 116, 2712-2723.	3.3	3
216	Cost effectiveness of three months of rifapentine and isoniazid for latent tuberculosis in Syrian refugees. <i>Journal of Clinical Tuberculosis and Other Mycobacterial Diseases</i> , 2021, 24, 100262.	1.3	3

#	ARTICLE	IF	CITATIONS
217	Sub-district level correlation between tuberculosis notifications and socio-demographic factors in Dhaka City corporation, Bangladesh. <i>Epidemiology and Infection</i> , 2021, 149, .	2.1	3
218	Improving the US Health Care System: Action Plan to Enhance Efficiency, Reduce Errors, and Improve Quality. <i>Journal of Investigative Medicine</i> , 2003, 51, 72-78.	1.6	3
219	Modeling to inform economy-wide pandemic policy: Bringing epidemiologists and economists together. <i>Health Economics (United Kingdom)</i> , 2022, 31, 1291-1295.	1.7	3
220	Tests for latent tuberculosis infection and isoniazid preventive therapy. <i>Lancet Infectious Diseases</i> , The, 2012, 12, 827-828.	9.1	2
221	Setting clinical priorities: A framework for incorporating individual patient preferences. <i>Patient Education and Counseling</i> , 2013, 90, 141-143.	2.2	2
222	Multidrug-resistant tuberculosis in India: looking back, thinking ahead. <i>Lancet Public Health</i> , The, 2017, 2, e8-e9.	10.0	2
223	Chest X-ray for tuberculosis preventive therapy: use caution. <i>Lancet HIV</i> ,the, 2018, 5, e478-e479.	4.7	2
224	The economic case for typhoid conjugate vaccines in countries with medium and high incidence of infection. <i>Lancet Infectious Diseases</i> , The, 2019, 19, 675-676.	9.1	2
225	Policy Implications of Mathematical Modeling of Latent Tuberculosis Infection Testing and Treatment Strategies to Accelerate Tuberculosis Elimination. <i>Public Health Reports</i> , 2020, 135, 38S-43S.	2.5	2
226	Incorporating patient reporting patterns to evaluate spatially targeted TB interventions. <i>Annals of Epidemiology</i> , 2021, 54, 7-10.	1.9	2
227	The Health and Economic Benefits of Tests That Predict Future Progression to Tuberculosis Disease. <i>Epidemiology</i> , 2022, 33, 75-83.	2.7	2
228	Evaluation of underweight status may improve identification of the highest-risk patients during outpatient evaluation for pulmonary tuberculosis. <i>PLoS ONE</i> , 2020, 15, e0243542.	2.5	2
229	Model-based Analysis of Tuberculosis Genotype Clusters in the United States Reveals High Degree of Heterogeneity in Transmission and State-level Differences Across California, Florida, New York, and Texas. <i>Clinical Infectious Diseases</i> , 2022, 75, 1433-1441.	5.8	2
230	“œl refused to drink but they still forced me”: A mixed-methods approach to understanding the pathways to reduce alcohol use among Vietnamese people with HIV. <i>Social Science and Medicine</i> , 2022, 301, 114902.	3.8	2
231	Tuberculosis screening improves preventive therapy uptake (TB SCRIPT) trial among people living with HIV in Uganda: a study protocol of an individual randomized controlled trial. <i>Trials</i> , 2022, 23, 399.	1.6	2
232	Rejoinder. <i>Epidemiology</i> , 2012, 23, 927-928.	2.7	1
233	Tuberculosis control in crisis: economic honesty and comparative effectiveness [Correspondence]. <i>International Journal of Tuberculosis and Lung Disease</i> , 2012, 16, 1131-1132.	1.2	1
234	The eye of the beholder: tuberculosis screening for elderly long-term care residents [Editorial]. <i>International Journal of Tuberculosis and Lung Disease</i> , 2013, 17, 1121-1121.	1.2	1

#	ARTICLE	IF	CITATIONS
235	Post-2015 tuberculosis strategies in a pre-2015 world [Editorial]. <i>International Journal of Tuberculosis and Lung Disease</i> , 2013, 17, 143-143.	1.2	1
236	Bold thinking for bold results: modeling the elimination of tuberculosis. <i>International Journal of Tuberculosis and Lung Disease</i> , 2014, 18, 883-883.	1.2	1
237	Simple Inclusion of Complex Diagnostic Algorithms in Infectious Disease Models for Economic Evaluation. <i>Medical Decision Making</i> , 2018, 38, 930-941.	2.4	1
238	Ending the Human Immunodeficiency Virus Epidemic: Towards an Evidence-Based Approach. <i>Clinical Infectious Diseases</i> , 2019, 69, 2199-2200.	5.8	1
239	Clinical Consequences of Using an Indeterminate Range for Early Infant Diagnosis of HIV: A Decision Model. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 82, 287-296.	2.1	1
240	Clinical Impact of Rapid Drug Susceptibility Testing to Accompany Fluoroquinolone-Containing Universal Tuberculosis Regimens: A Markov Model. <i>Clinical Infectious Diseases</i> , 2020, 71, 2889-2896.	5.8	1
241	Longitudinal analysis of alcohol use and intimate partner violence perpetration among men with HIV in northern Vietnam. <i>Drug and Alcohol Dependence</i> , 2020, 213, 108098.	3.2	1
242	Cost-effectiveness of universal HIV testing and treatment: where next?. <i>The Lancet Global Health</i> , 2021, 9, e573-e574.	6.3	1
243	Reply to Pierce: Subclinical Tuberculosis: Some Flies in the Ointment. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 203, 1328-1329.	5.6	1
244	Design and execution of a public randomization ceremony to enhance stakeholder engagement within a cluster randomized trial to improve tuberculosis diagnosis in Uganda. <i>Contemporary Clinical Trials Communications</i> , 2021, 22, 100707.	1.1	1
245	Conditional Cash Transfers to Incentivize Tuberculosis Screening: Description of a Novel Strategy for Contact Investigation in Rural South Africa. <i>Clinical Infectious Diseases</i> , 2022, 74, 957-964.	5.8	1
246	Use of Rapid, Point-of-Care Assays by Private Practitioners in Chennai, India: Priorities for Tuberculosis Diagnostic Testing. <i>PLoS ONE</i> , 2016, 11, e0155775.	2.5	1
247	Assessing the Impact of Targeted Screening and Treatment of Diabetes and Hypertension Among Adults Living with HIV in Nairobi, Kenya. , 2020, , .		1
248	Disadvantage and the experience of treatment for multidrug-resistant tuberculosis (MDR-TB). <i>SSM Qualitative Research in Health</i> , 2022, 2, 100042.	1.5	1
249	Coughing is Not Required to Transmit <i>Mycobacterium tuberculosis</i> : Another Nail in the Coffin. <i>American Journal of Respiratory and Critical Care Medicine</i> , 0, , .	5.6	1
250	Healthy But Harmed. <i>JAMA - Journal of the American Medical Association</i> , 2014, 312, 1399.	7.4	0
251	In reply. <i>International Journal of Tuberculosis and Lung Disease</i> , 2015, 19, 1264-1264.	1.2	0
252	Evaluation of Health Promotion and Disease Prevention Programs. <i>Clinical Infectious Diseases</i> , 0, , civ740.	5.8	0

#	ARTICLE	IF	CITATIONS
253	Measuring success: The challenge of social protection in helping eliminate tuberculosis. PLoS Medicine, 2017, 14, e1002419.	8.4	0
254	Describing the global burden of MDR-TB: missing cases or different metrics?. International Journal of Tuberculosis and Lung Disease, 2017, 21, 1-1.	1.2	0
255	Reply to Chen, Song, and Liu. Clinical Infectious Diseases, 2020, 70, 547-548.	5.8	0
256	The urgent need to improve clinical practice guidelines for pediatric tuberculosis. International Journal of Tuberculosis and Lung Disease, 2020, 24, 264-264.	1.2	0
257	Refocusing the timeline of tuberculosis through the lens of BCG. Thorax, 2021, 76, thoraxjnl-2021-217289.	5.6	0
258	Brief Report: Proportion and Predictors of Adult TB Contacts Accepting HIV Testing During an Active TB Case Finding Intervention in South Africa. Journal of Acquired Immune Deficiency Syndromes (1999), 2020, 85, 525-529.	2.1	0
259	Alcohol use, depressive symptoms, and intimate partner violence perpetration: A longitudinal analysis among men with HIV in northern Vietnam. PLoS ONE, 2020, 15, e0240674.	2.5	0
260	CKD and Risk of Incident Hospitalization With Clostridioides Difficile Infection: Findings From the Atherosclerosis Risk in Communities (ARIC) Study. American Journal of Kidney Diseases, 2021, , .	1.9	0
261	Title is missing!. , 2020, 17, e1003420.		0
262	Title is missing!. , 2020, 17, e1003420.		0
263	Title is missing!. , 2020, 17, e1003420.		0
264	Title is missing!. , 2020, 17, e1003420.		0
265	Title is missing!. , 2020, 17, e1003420.		0
266	Title is missing!. , 2020, 15, e0243542.		0
267	Title is missing!. , 2020, 15, e0243542.		0
268	Title is missing!. , 2020, 15, e0243542.		0
269	Title is missing!. , 2020, 15, e0243542.		0